Fundraising Fox
Pleopharma
Phoenixville, US · Founded 2020 · Delaware corporation · 12 employees on LinkedIn · 1 known investors
Find your way into Pleopharma
Sign up to see every warm intro you have to Pleopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pleopharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PleoPharma is a pharmaceutical company developing a treatment aimed at an unmet medical condition. It works with industry partners, healthcare providers, researchers, and investors.
Founders & leadership
JC
Jay ConstantineExecutive
TF
Thomas F PocheExecutiveThomas F Poche is an Executive Officer at PleoPharma, a pharmaceutical company developing treatments for unmet medical conditions. He brings over 25 years of experience in intellectual property development and enforcement, regulatory strategy, and corporate development in biotech and pharma.
DA
Daniel Alan CartwrightExecutive
GC
Ginger ConstantineChief Executive OfficerformerGinger Constantine is a physician with over 25 years of experience in pharmaceutical regulatory and clinical development, including roles at Wyeth Pharmaceuticals (acquired by Pfizer) overseeing women's health and bone repair clinical research. She founded EndoRheum Consultants, a clinical development consulting firm, in 2010.
PB
Paul BisaroNamed on SEC filing
TT
Tommy ThompsonNamed on SEC filing
KM
Kyle MowitzNamed on SEC filing
KT
Kyle TomlinNamed on SEC filing
PT
Poche ThomasNamed on SEC filing
MT
McInerney TimothyNamed on SEC filing
Board
SH
TM
Timothy McInerneyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$22.9M disclosed across 4 rounds · 2020–2026
▶$5.5MraisedAug 2026 · 11 investors · PharmaceuticalsRule 506(b)
▶$5.5MraisedAug 2026 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ginger ConstantineExecutive Officer, Director
- Jay ConstantineExecutive Officer, Director
- Robert FinizioExecutive Officer, Director
- Paul BisaroDirector
- Tommy ThompsonDirector
- Sarah HassanDirector
- Brij SharmaDirector
- Kyle MowitzDirector
- Kyle TomlinDirector
- Poche ThomasExecutive Officer
- Daniel CartwrightExecutive Officer
- McInerney TimothyDirector
- Offering amount
- $15M
- Amount sold
- $5.5M
- Minimum investment
- $50K
- Sales commissions
- $50K
- Placement agents
- Supervision Partners LLC
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.2MraisedAug 2025 · 9 investors · PharmaceuticalsRule 506(b)
▶$6.2MraisedAug 2025 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jay ConstantineExecutive Officer, Director
- Thomas F PocheExecutive Officer
- Daniel Alan CartwrightExecutive Officer
- Sarah HassanDirector
- Timothy McInerneyDirector
- Bisaro PaulDirector
- Robert FinizioDirector
- Thompson TommyDirector
- Ginger ConstantineExecutive Officer, Director
- Brij SharmaDirector
- Offering amount
- $36.2M
- Amount sold
- $6.2M
- Minimum investment
- $50K
- Sales commissions
- $268K
- Placement agents
- Castle Hill Capital Partners, Inc, Supervision Partners LLC
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.1MraisedMay 2022 · 47 investors · PharmaceuticalsRule 506(b)
▶$11.1MraisedMay 2022 · 47 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JAY CONSTANTINEDirector
- ROBERT FINIZIODirector
- GINGER CONSTANTINEExecutive Officer, Director
- THOMAS POCHEExecutive Officer
- PAUL BISARODirector
- DANIEL CARTWRITGHTExecutive Officer
- Offering amount
- $16.1M
- Amount sold
- $11.1M
- Sales commissions
- $131.1K
- Placement agents
- CASTLE HILL CAPITAL PARTNERS, INC.
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$130KraisedFeb 2020 · 1 investors · Other Health CareRule 506(b)
▶$130KraisedFeb 2020 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jay ConstantineDirector, Promoter
- Robert FinizioDirector, Promoter
- Ginger ConstantineExecutive Officer, Director, Promoter
- Amount sold
- $130K
- Minimum investment
- $1K
- First sale
- Jan 2020
- Incorporated
- Limited Liability Company, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Pharm IntA contract drug manufacturing organization (CDMO) specializing in complex pharmaceutical formulations and potent compounds, serving drugmakers from small batches through full-scale production. The company holds FDA licensure and operates multiple manufacturing facilities with capabilities in oral dosage, aseptic processing, and analytical services.
BionpharmaBionpharma researches, develops, and manufactures generic prescription drugs and over-the-counter products, and is one of the largest US suppliers of softgel capsules. It also sells OTC products online through its A+ Health brand on Amazon.
Companies working in the same space as Pleopharma.
Frequently asked questions
- What does Pleopharma do?
- PleoPharma is a pharmaceutical company developing a treatment aimed at an unmet medical condition. It works with industry partners, healthcare providers, researchers, and investors.
- Who are Pleopharma's investors?
- Pleopharma's investors include Florida Opportunity Fund.
- How much funding has Pleopharma raised?
- Pleopharma has disclosed $22.9M raised across 4 rounds.
- Where is Pleopharma headquartered?
- Pleopharma is headquartered in Phoenixville, US.